Lexaria Bioscience (LEXXW) Stock Price, News & Analysis

Company Overview

Lexaria Bioscience Corp. (NASDAQ:LEXXW) is a pharmaceutical development company focused on the design and commercialization of drug delivery technologies. Its core innovation, the DehydraTECH platform, is engineered to enhance the absorption and bioavailability of lipophilic molecules such as cannabinoids, nicotine and other therapeutics. By using proprietary lipid-based formulations, DehydraTECH aims to accelerate onset of action while reducing the impact of first-pass metabolism.

The company’s activities encompass research, development and licensing of its patented delivery systems to pharmaceutical, wellness and consumer health sectors. Lexaria conducts preclinical and clinical studies to evaluate DehydraTECH’s potential across a range of applications, including pain management, cardiovascular health and anti-inflammatory therapies. In addition to internally developed product candidates, Lexaria seeks partnerships to integrate its technology into third-party formulations.

Headquartered in Kelowna, British Columbia, Lexaria also operates facilities in Kentucky for formulation development and testing. The company collaborates with academic institutions and industry partners throughout North America and Europe, building a network aimed at validating the safety and efficacy of its delivery platform in diverse patient populations.

Lexaria is led by founder, President and Chief Executive Officer Christopher Bunka, supported by an executive team with combined expertise in pharmaceutical R&D, regulatory affairs and finance. The company continues to pursue strategic alliances and licensing agreements designed to extend the reach of its DehydraTECH technology across global markets.

Key Stats

• Today's Range: $0.07 to $0.15
• 50-Day Range: $0.08 to $0.23
• 52-Week Range: $0.07 to $2.00
• Volume: 300 shs
• Average Volume: 10,068 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

LEXXW Stock Analysis - Frequently Asked Questions

How have LEXXW shares performed this year?

Lexaria Bioscience's stock was trading at $0.7641 at the beginning of the year. Since then, LEXXW shares have decreased by 80.5% and is now trading at $0.1492.

How do I buy shares of Lexaria Bioscience?

Shares of LEXXW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:LEXXW
• CIK: 1348362
• Web: N/A
• Phone: 250-765-6424
• Fax: N/A
• Employees: 7
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $615.92 thousand
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A